Increasing incidence of lentigo maligna and lentigo maligna melanoma in Catalonia.


Journal

International journal of dermatology
ISSN: 1365-4632
Titre abrégé: Int J Dermatol
Pays: England
ID NLM: 0243704

Informations de publication

Date de publication:
May 2019
Historique:
received: 23 05 2018
revised: 30 10 2018
accepted: 14 11 2018
pubmed: 15 12 2018
medline: 18 10 2019
entrez: 15 12 2018
Statut: ppublish

Résumé

Recent epidemiological studies suggest that past data where superficial spreading melanoma was by far the most common subtype of melanoma may not reflect current patterns of sun exposure or other risk factors more involved in other subtypes of melanoma as lentigo maligna (LM) or lentigo maligna melanoma (LMM). In order to measure the current situation in our country, all cases of LM and LMM diagnosed in 23 hospitals in Catalonia, from 2000 to 2007, were recorded. Although for the global period LM/LMM represented only 8.4% of cases, an increasing trend in this percentage was observed throughout the study period (from 6.9% [27 cases] in 2000 to 13.1% [94 cases] in 2007). Also, an increasing incidence of LM/LMM was observed, especially in chronically sun-exposed areas (85.5% involving the head and neck region). During the 8 years of the registry, the mean Breslow thickness of LMM remained stable. However, the increase in the number of LM (in situ) cases was significantly higher than the increase of the invasive ones. An important observation from this data is that aging of population and current sun exposure patterns could keep increasing the incidence of LM/LMM, which may become an important public healthcare problem, over the other histological subtypes. In order to establish primary or secondary preventive measures to the LM/LMM risk-population, it is imperative to highlight the importance of chronic sun damage as a melanoma risk factor, and not only sunburn, most commonly addressed in melanoma prevention campaigns.

Sections du résumé

BACKGROUND BACKGROUND
Recent epidemiological studies suggest that past data where superficial spreading melanoma was by far the most common subtype of melanoma may not reflect current patterns of sun exposure or other risk factors more involved in other subtypes of melanoma as lentigo maligna (LM) or lentigo maligna melanoma (LMM).
METHODS METHODS
In order to measure the current situation in our country, all cases of LM and LMM diagnosed in 23 hospitals in Catalonia, from 2000 to 2007, were recorded.
RESULTS RESULTS
Although for the global period LM/LMM represented only 8.4% of cases, an increasing trend in this percentage was observed throughout the study period (from 6.9% [27 cases] in 2000 to 13.1% [94 cases] in 2007). Also, an increasing incidence of LM/LMM was observed, especially in chronically sun-exposed areas (85.5% involving the head and neck region). During the 8 years of the registry, the mean Breslow thickness of LMM remained stable. However, the increase in the number of LM (in situ) cases was significantly higher than the increase of the invasive ones.
CONCLUSIONS CONCLUSIONS
An important observation from this data is that aging of population and current sun exposure patterns could keep increasing the incidence of LM/LMM, which may become an important public healthcare problem, over the other histological subtypes. In order to establish primary or secondary preventive measures to the LM/LMM risk-population, it is imperative to highlight the importance of chronic sun damage as a melanoma risk factor, and not only sunburn, most commonly addressed in melanoma prevention campaigns.

Identifiants

pubmed: 30548854
doi: 10.1111/ijd.14334
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

577-581

Subventions

Organisme : ISCIII
ID : FIS-PI12/00260
Organisme : ISCIII
ID : FIS-PI15/00711
Organisme : FEDER "Una manera de hacer Europa"
Organisme : CIBERONC
ID : CB16/12/00231
Organisme : Fundació la Marató de TV3
ID : FMTV 201331-31
Organisme : Fundació la Marató de TV3
ID : 201331-30
Organisme : Spanish Fondo de Investigaciones Sanitarias
ID : PI15/00716
Organisme : Spanish Fondo de Investigaciones Sanitarias
ID : PI15/00956
Organisme : CIBER de Enfermedades Raras of the Instituto de Salud Carlos III
Organisme : European Development Regional Fund
Organisme : Catalan Government
ID : AGAUR 2014_SGR_603
Organisme : European Commission
ID : LSHC-CT-2006-018702
Organisme : Fundación Científica de la Asociación Española Contra el Cáncer
ID : GCB15152978SOEN
Organisme : CERCA Programme/Generalitat de Catalunya

Informations de copyright

© 2018 The International Society of Dermatology.

Auteurs

Clara Matas-Nadal (C)

Department of Dermatology, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, Lleida & CIBERONC, Lleida, Spain.

Josep Malvehy (J)

Department of Dermatology, Hospital Clínic de Barcelona (Melanoma Unit), University of Barcelona, IDIBAPS, Barcelona & CIBERER, Barcelona, Spain.

Jose Ramon Ferreres (JR)

Department of Dermatology, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain.

Aram Boada (A)

Department of Dermatology, Universitari Germans Trias i Pujol, Badalona, Spain.

Domingo Bodet (D)

Department of Dermatology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Sonia Segura (S)

Department of Dermatology, Hospital del Mar, IMIM, Barcelona, Spain.

Montse Salleras (M)

Department of Dermatology, Hospital Universitari Sagrat Cor, Barcelona, Spain.

Antoni Azon (A)

Department of Dermatology, Hospital Universitari Sant Joan de Reus, Reus, Spain.

Susana Bel-Pla (S)

Department of Dermatology, Hospital Comarcal d'Amposta, Amposta, Spain.

Xavier Bigata (X)

Department of Dermatology, Hospital de Mataró, Mataró, Spain.

Antoni Campoy (A)

Department of Dermatology, Hospital General de Catalunya, Sant Cugat, Spain.

Neus Curcó (N)

Department of Dermatology, Hospital Universitari Mútua Terrassa, Terrassa, Spain.

Joan Dalmau (J)

Department of Dermatology, Hospital Santa Creu i Sant Pau, Barcelona, Spain.

Manel Formigon (M)

Department of Dermatology, Consorci Sanitari de Terrassa, Terrassa, Spain.

Alberto Gonzalez (A)

Department of Dermatology, Consorci Sanitari Integral, L'Hospitalet de Llobregat, Spain.

Miquel Just (M)

Department of Dermatology, Hospital de Figueres, Figueres, Girona, Spain.

Enric Llistosella (E)

Department of Dermatology, Hospital Universitari Dr. Josep Trueta, Girona, Spain.

M Elena Nogues (ME)

Department of Dermatology, Hospital d'Igualada, Igualada, Barcelona, Spain.

Ramon Pedragosa (R)

Department of Dermatology, Hospital Plató, Barcelona, Spain.

Josep A Pujol (JA)

Department of Dermatology, Hospital Universitari Joan XXIII, Tarragona, Spain.

Mireia Sabat (M)

Department of Dermatology, Hospital Parc Taulí, Sabadell, Spain.

Joan A Smandia (JA)

Department of Dermatology, Hospital 2 de Maig, Barcelona, Spain.

Pedro Zaballos (P)

Department of Dermatology, Hospital de Santa Tecla, Tarragona, Spain.

Susana Puig (S)

Department of Dermatology, Hospital Clínic de Barcelona (Melanoma Unit), University of Barcelona, IDIBAPS, Barcelona & CIBERER, Barcelona, Spain.

Rosa M Martí (RM)

Department of Dermatology, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, Lleida & CIBERONC, Lleida, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH